Desktop Metal has paid an undisclosed amount to buy UT Dallas spinout Adaptive3D.

York spinout Cizzle Biotechnology has undertaken a reverse merger with Bould Opportunities to list on the London Stock Exchange.

MIT spinout Ginkgo Bioworks will go public through a reverse merger with Soaring Eagle Acquisition Corp to list on the Nasdaq Capital Market.

AbbVie subsidiary Allergan Aesthetics has agreed to acquire Soliton, which is commercialising a cellulite treatment based on research at University of Texas.

Cambridge’s gene therapy developer had set terms for an offering set to raise between $135m and $149m on the Nasdaq Global Select Market.

The stem cell-transplant technology developer, partly based on Stanford research, is going public through a reverse merger that will give it a $490m market capitalisation.

Talaris has raised $150m in an initial public offering almost two decades after being spun out of University of Louisville as Regenerx.

The UPMC-backed cancer biotherapeutics developer priced its shares in the middle of their range in its initial public offering.

Athenex will pay $70m upfront and up to $115m in milestone payments to acquire Kuur Therapeutics, providing exits to Baylor College and IP Group.

NeoGenomics has exercised its option to buy Inivata, a precision cancer diagnostics company that was formed to exploit Cambridge and CRUK research seven years ago.